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ABSTRACT
The ARF tumour suppressor stabilizes p53 by nega-
tively regulating the E3 ubiquitin ligase MDM2 to
promote cell cycle arrest and cell death. However,
ARF is also able to arrest cell proliferation by inhibit-
ing ribosome biogenesis. In greater part this is
achieved by targeting the transcription termination
factor I (TTF-I) for nucleolar export, leading to an
inhibition of both ribosomal RNA synthesis and pro-
cessing. We now show that in the absence of ARF,
TTF-I is ubiquitinylated by MDM2. MDM2 interacts
directly with TTF-I and regulates its cellular abun-
dance by targeting it for degradation by the prote-
asome. Enhanced TTF-I levels inhibit ribosome
biogenesis by suppressing ribosomal RNA synthe-
sis and processing, strongly suggesting that exact
TTF-I levels are critical for efficient ribosome bio-
genesis. We further show that concomitant with its
ability to displace TTF-I from the nucleolus, ARF
inhibits MDM2 ubiquitinylation of TTF-I by competi-
tively binding to a site overlapping the MDM2 inter-
action site. Thus, both the sub-nuclear localization
and the abundance of TTF-I are key regulators of
ribosome biogenesis.
INTRODUCTION
Ribosome biogenesis, the synthesis and assembly of ribo-
somes, is an essential task for any proliferative cell and, as
might be expected, it is highly responsive to environmental
changes and to various forms of stress (1). It is therefore
not surprising to ﬁnd that many tumour suppressors and
oncogenes, including Rb, ARF, p53 and MDM2, work in
collusion or opposition to maintain a level of ribosome
biogenesis appropriate to the cellular state, whether it be
proliferative, cell cycle arrested, differentiated or apop-
totic. Although the rate of ribosome biogenesis was
demonstrated to determine passage through the cell
cycle checkpoint ‘Start’ and the commitment of a cell to
proliferation (2), there is still a dearth of information on
how exactly this control is achieved.
The catalytic core of the ribosome is formed by the 28S
and 18S ribosomal RNAs (rRNAs), which along with the
small 5.8S rRNA are processed from a single 45S (47S)
precursor transcript. There is good evidence that a key
regulator of ribosome biogenesis is the rate at which
these rRNAs are synthesized (reviewed in refs 1,3,4). In
human and mouse, the 200 or so gene copies encoding the
45S pre-rRNA are organized in ﬁve tandem arrays on the
short arms of acrocentric chromosomes. These genes are
transcribed by RNA polymerase I (RPI), and the
RPI-speciﬁc basal factors SL1/TIF-IB and UBF
(1,5–10). The 45S rRNA is cotranscriptionally assembled
with pre-ribosomal proteins before undergoing processing
via major 32S and 20S intermediates. Prior to cleavage the
pre-rRNA is also extensively modiﬁed by methylation and
pseudouridinylation, a process that is directed by several
hundred small nucleolar RNAs (snoRNAs).
The ARF tumour suppressor has been implicated in
regulating the production of the rRNAs (11,12). While
searching for novel ARF interactor proteins we recently
identiﬁed transcription termination factor I (TTF-I), a nu-
cleolar factor able to terminate RPI transcription of the
rRNA genes (13). ARF was found to control the
sub-nuclear localization of TTF-I, and it was shown that
in fact TTF-I shuttles rapidly between nucleoplasm and
nucleolus with the aid of the chaperone NPM/B23 and a
nucleolar localization sequence within its N-terminal regu-
latory domain. ARF inhibits the nucleolar import of
TTF-I by binding to and inhibiting this nucleolar local-
ization sequence, causing the accumulation of TTF-I in
the nucleoplasm. Conditional depletion of TTF-I further
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factor for transcription of the rRNA genes but, more sur-
prisingly, also for processing of the precursor rRNA.
TTF-I was originally identiﬁed by its ability to termin-
ate RPI transcription of the pre-rRNA in vitro (14–16).
Mouse TTF-I contains a C-terminal DNA-binding
domain with homology to the DNA-binding domain or
the Myb oncogene and binds to multiple sites both
upstream and downstream of the rRNA genes. Although
TTF-I was clearly shown to terminate RPI transcription
in vitro and to bind to sites downstream of the rRNA
genes (14–16), it is still uncertain whether this is its
major role. TTF-I binding to a conserved upstream
promoter proximal site on the rRNA genes has been
shown to be important in regulating rRNA gene
activity. Binding to this site has been shown to phase
nucleosomes on the RPI promoter and thus activate
transcription (17). TTF-I was shown to recruit the
ATP-dependent nucleosome remodelling complex NoRC
(18) and in this way can alter nucleosome positioning.
However, recruitment of this same chromatin remodelling
complex along with the deacetylase HDAC1 and a DNA
methyltransferase has also been shown to repress the
rRNA genes (19,20). Thus, the in vivo functions of
TTF-I still remain somewhat obscure. We now show
that the abundance of TTF-I is a key factor in determining
pre-rRNA synthesis and processing. TTF-I levels are
regulated by the E3-ubiquitin ligase MDM2 via direct
ubiquitinylation, a function that is directly competed by
ARF. Our data identify TTF-I as a target of the
ARF-MDM2 tumour suppressor–oncogene balance and





ARF (mARF) a.a 1–169 was cloned
into pcDNA3 (Invitrogen). N-terminal FLAG or YFP
tagged mouse TTF-I (TTF-I) were expressed using
pFLAGCMV2 (Invitrogen), pRevTRE (Clontech) or
pEYFP-C1 (Clontech). The expression vectors for
GFP-UBF, HA-Ubiquitin (21), pCOC-X2-MDM2WT
and C642A (22,23), Myc-MDM2 (pDWM659) (24) were
provided respectively by T. Mistelli, J.-Y. Masson, S. Laı´n
and C. Blattner.
Antibodies
Rabbit anti-TTF-I#3 (13), and other antibodies were:
anti-FLAG (F7425, Sigma-Aldrich), anti-ﬁbrillarin
(MMS-581S, Covance), anti-HA (ab9134, Abcam),
anti-HA (ab9110, Abcam), anti-MDM2 (3G5, 4B11 and
2A10) (25), anti-ubiquitin (FK2 #ST1200, Calbiochem),
anti-actin (#A2228 Clone AC-74, Sigma), IgG mouse
(#10400C, Invitrogen), anti-YFP (632460, Clontech),
anti-Myc (71D10, Cell Signaling), anti-C23/nucleolin
(MS-3; sc8031, Santa Cruz) and anti-His (631212,
Clontech).
Cell lines
NIH3T3 and HEK293T cells were obtained from ATCC.
NIH3T3 cells were transfected with linearized
pRevTREFLAG-TTF-I and pTet-OffNeo (Clontech).
Clones were selected with hygromycin (100mg/ml) in the
presence of doxycycline (Dox; 50mg/ml). Clones B6 and
F9 were identiﬁed as displaying a signiﬁcant level of
FLAG-TTF-I expression in the absence of Dox. Cell
lines were maintained in high glucose Dulbecco’s
modiﬁed eagle’s Medium (DMEM) supplemented with
10% fetal bovine serum (FBS) and 100u.ml
 1 each of
penicillin and streptomycin (PS). Tet-Off clones B6 and
F9 were maintained in the same medium with the
addition of 50mg/ml Dox. Where indicated, MT-ARF
(26) cells were treated with 80mM ZnSO4, clones B6 and
F9 were grown in the absence of doxycylin and HEK293T
and NIH3T3 cells were treated respectively with 10 or
20mM MG132 for 12h to inhibit the 26S proteasome or
with 50mM cycloheximide (Chx) for indicated times to
inhibit protein synthesis.
In vivo RNA labelling, extraction and analysis
These were performed as previously described (27,28).
Brieﬂy, NIH3T3 (ATCC) cells and cell clones were
grown in the presence or absence of Dox and labelled
for 3h by the addition of 2.5mCi.ml
 1 [
3H]-uridine
(Perkin Elmer), before RNA extraction in 1ml Trizol
(Invitrogen) according to the manufacturer’s protocol.
Two to four micrograms of this RNA was loaded onto
1% formaldehyde gels and electrophoresed overnight at
2.5V/cm in MOPS running buffer. After EtBr staining,
gels were photographed, UV-irradiated for 5min
at maximum energy (UV-cross-linker, Hoefer) and RNA
transferred to Biodyne B membranes (Pall) by vacuum
transfer (Biometra). To provide a visual image of the
labelling, the membrane was UV-crosslinked
(70mJ.cm
 2), treated with ENHance (Perkin-Elmer) and
ﬂuorographed at  80 C for 24–72h. Finally, to quantitate
RNA labelling, the [
3H]-labelled RNA bands were cut
from the membrane, using the ﬂuorograph as guide, and
were scintillation counted in ScintiVerse (Fisher) using
external standard correction. All experiments were
performed and analysed throughout in triplicate.
Methionine labelling
MT-ARF cells were plated in a 60-mm dish and induced
for 0, 6, 12 and 24h. Cells were washed twice with
prewarmed PBS and incubated in 2ml of prewarmed
methionine-free DMEM supplemented with 10% FBS at
37 C and 5% CO2. After 60-min incubation the medium
was changed for 2ml of prewarmed methionine-free
DMEM supplemented with 10% FBS and 1mCi of
[
35S]-methionine and incubation continued for 90min at
37 C and 5% CO2. Then cell extracts were analysed by
western blotting and membrane was cut to estimate total
protein synthesis by scintillation counting in ScintiVerse
(Fisher).
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For total protein extracts, cells were washed with 3ml
cold PBS, scraped into 1ml cold PBS, centrifuged 30s
at 14000r.p.m. and resuspended in sodium dodecyl
sulphate (SDS) loading buffer. After fractionation on
8% or 5–15% gradient SDS–polyacrylamide gel electro-




6 HEK293T cells were seeded onto
poly-L-lysine-treated (1mg.ml
 1, Sigma-Aldrich) 60-mm
culture dishes 24h prior to transfection. Transfection
used CaPO4/chloroquine (29) and 8 or 12mg total DNA
per 60mm culture dish. NIH3T3, MT-ARF, Clone B6 and
Clone F9 cells were plated at  1.5 10
5 per 35mm dish
( 25% conﬂuency) for GFP constructs, or  2.5 10
5 per
35mm dish ( 40% conﬂuency) for immunoﬂuorescence
(IF) using Ex-GEN 500 (Fermentas).
Immunoprecipitation
Cells were scraped into IP buffer [25mM Tris–HCl,
pH 7.5, 1mM EDTA, 0.1mM EGTA, 5mM MgCl2,
150mM NaCl, 10% glycerol, 1% NP-40 (Igepal.
Sigma-Aldrich), 0.1% SDS, 1% TritonX100 and 1mg/ml
each pepstatin, leupeptin and aprotinin (Sigma-Aldrich)],
kept on ice for 15min and then sonicated 4 20s (S-450
Branson Ultrasonics or Sonic Dismembrator Model 100
Fisher Scientiﬁc) at maximum power or continuous power
1, respectively. Cell lysates were cleared, 14000r.p.m.,
1min and incubated with ﬁrst antibody for 3h at 4 C.
Immunoprecipitates were recovered on Protein
A-Sepharose (Amersham Biosciences) and washed once
in IP buffer and three times in IP buffer less detergents.
After fractionation on 8%, 12%, or 5–15% gradient SDS–
PAGE, immunoprecipitates and total cell lysates were
analysed by standard western blotting procedures.
Pull-down assays
His-TTF-I (a.a. 471–859) was expressed in Escherichia coli
BL21-CodonPlus (Stratagene) and isolated on Ni-NTA
Agarose (Qiagen) following the manufacturer’s protocol.
Control Ni-NTA Agarose beads were prepared in the
same way but using an extract from untransformed
E. coli BL21-CodonPlus cells. Myc-MDM2 was expressed
in vitro using the TNT Coupled Reticulocyte Lysate
System (Promega). Equal aliquots of Myc-MDM2 were
transferred to binding buffer [25mM Tris–HCl pH 7.5,
150mM NaCl, 1% IGEPAL (Sigma)] and preabsorbed
using Ni-NTA beads. The Control or His-TTF-I
Ni-NTA beads were then added to the preabsorbed
Myc-MDM2 and incubated at 4 C for 4h. The beads
were then recovered and washed ﬁve times with the
binding buffer before gel analysis by western blot using
anti-His and anti-Myc antibodies.
Immunoﬂuorescence microscopy
For immunoﬂuorescence cells were ﬁxed with 4%
paraformaldehyde/PBS for 15min (only in the case of IF
in Supplementary Figure S5, cells were then heated to
100 C for 10min in 10mM Na-citrate pH 6.0),
permeabilized with 0.5% Triton/PBS for 5min, incubated
with primary antibodies (100ml) in 5% goat serum/PBS
for 1h at room temperature (RT), stained with
anti-rabbit/mouse IgG AlexaFluor 488/568 (Molecular
Probes) and counter-stained with DAPI. After mounting
in 50% glycerol/50% 0.2M Na-glycine, 0.3M NaCl and
observed using a Leica DMI6000 B and OpenLab and
Volocity software (Perkin-Elmer Improvision).
S1 mapping
The termination site of the 45S was mapped using a 30
32P-labelled probe extending from +13169 to +13696
covering the ﬁrst ﬁve Sal boxes (T1–5) essentially as
(30,31).
Psoralen crosslinking and Southern blotting
Psoralen crosslinking and Southern blotting were per-
formed as described elsewhere (32,33).
RESULTS
The abundance of TTF-I is critical for
ribosome biogenesis
In a previous study we showed that ARF arrested cell
division by inhibiting the nucleolar localization of TTF-I
and in so doing suppressed both 45S pre-rRNA transcrip-
tion and its subsequent processing into the mature rRNAs
(13). This same study also showed that the conditional
depletion of TTF-I phenocopied ARF induction by in-
hibiting both pre-rRNA transcription and processing.
These data showed that TTF-I is an essential factor in
rRNA synthesis. The data also suggested that TTF-I
abundance might be a positive regulator of rRNA synthe-
sis and hence of ribosome biogenesis. To test this latter
possibility we sought to establish cell lines in which TTF-I
levels could be upregulated.
An epitope-tagged mouse TTF-I transgene was
introduced into NIH3T3 cells under the negative control
of Dox (tet-off) and stable cell clones screened for trans-
gene expression after removal of doxycycline. Two cell
clones, B6 and F9, displaying different levels of
FLAG-TTF-I induction after Dox withdrawal were
selected for further study. As expected, the exogenous
FLAG-TTF-I was found to be present within the nucle-
olus, and while clone B6 displayed a low level of exogen-
ous TTF-I expression, expression in clone F9 was
signiﬁcantly more robust (Figure 1A). In both cell clones
the bulk levels of TTF-I were clearly enhanced above
those in the parent NIH3T3 cells, although this enhance-
ment was signiﬁcantly more apparent in the F9 clone
(Figure 1A and lower panels of 1B). However, metabolic
labelling of newly synthesized rRNA revealed that the
enhanced TTF-I levels did not enhance rRNA synthesis
in either clone. Indeed, synthesis of the 45S pre-rRNA was
suppressed in both clones in proportion to their TTF-I
expression levels (Figure 1B, upper panel, Figure 1C
and Supplementary Figure S1D). As mentioned above,
Nucleic Acids Research, 2012,Vol.40, No. 12 5359TTF-I has been implicated not only in gene activation,
but also in gene silencing. Hence it was possible that
increased TTF-I levels had increased the number of
silent rRNA genes. However, the psoralen crosslinking
technique (32,34) revealed no change in the fraction
of active rRNA genes that could explain the





Figure 1. Enhanced expression of TTF-I is inhibitory to rRNA synthesis and processing. (A) Conditional expression of FLAG-TTF-I in tet-off
regulated cell clones B6 and F9, and localization of endogenous ﬁbrillarin (Fib) before and after induction of the UBF transgene by withdrawal of
doxycyclin (Dox+, Dox–). (B) B6, F9 cell clones and the NIH3T3 cell line were maintained in the presence or absence of doxycyclin were subjected
to a 3-h [
3H]-uridine pulse-labelling and incorporation into rRNA determined in parallel with the immunoblot analysis of total TTF-I (anti-TTF#3),
FLAG-TTF-I and ﬁbrillarin protein levels. (C) Quantitation of three independent pulse-label analyses as in B. 45S rRNA synthesis is shown in the
left-hand panel and the ratios of 28S:45S and 18S:45S rRNAs before and after doxycycline removal are shown in the middle- and right-hand panels
for cell clones B6 and F9 and NIH3T3 cells.
5360 Nucleic Acids Research, 2012,Vol.40, No. 12Surprisingly, processing of the 45S rRNA to yield the
mature 28S and 18S rRNAs was also suppressed by
enhanced levels of TTF-I. Metabolic labelling revealed a
severe and differential reduction in the synthesis of mature
28S and 18S rRNAs relative to the 45S precursor
(Figure 1B and C). This was also found to be a character-
istic of TTF-I depletion (13) and indeed endogenous
TTF-I is found to be broadly distributed throughout the
nucleolus and is certainly not limited to the rRNA genes,
suggesting that it may also play a role in maturation of the
rRNA (Supplementary Figure S2A and S2B).
TTF-I is ubiquitinylated and its abundance is limited
by MDM2
Since both depletion and augmentation of TTF-I levels
suppress 45S rRNA synthesis and processing, the levels
of this protein must normally be ﬁnely tuned to cellular
needs. Since protein abundance is a balance between syn-
thesis and degradation, we determined the rate of turnover
of the TTF-I protein. Clone B6 was grown in the absence
of Dox until exogenous TTF-I reached steady-state levels.
Dox was then added to the culture to inactivate the trans-
gene and TTF-I levels followed over time. Exogenous
FLAG-TTF-I decayed to about 25% of the steady-state
level 12h after transgene inactivation and its depletion
was essentially complete by 24h (Figure 2A). Assuming
an exponential decay, this means that the TTF-I protein
has a half-life of between 6 and 7h, much shorter than the
cell cycle. TTF-I degradation is therefore a likely deter-
minant of its cellular abundance.
Regulated degradation is often the result of poly-
ubiquitinylation, which targets proteins to the proteasome
(35). Indeed, when TTF-I was co-expressed with epitope-
tagged ubiquitin, it was found to be poly-ubiquitinylated,
suggesting that this modiﬁcation was important in
determining its rate of degradation (Figure 2B). Most
strikingly, co-expression of ARF almost completely
repressed this ubiquitinylation. Since ARF is known to
inactivate the E3 ubiquitin ligase MDM2, this suggested
that TTF-I might be a direct target of this E3 ligase.
Consistent with this, co-expression of increasing levels of
MDM2 reduced the accumulation of FLAG-TTF-I
(Figure 2C). Further, expression of MDM2 reduced the
level of endogenous TTF-I within the nucleoli of these
cells (Figure 2D and Supplementary Figure S3).
MDM2 induces ubiquitinylation of TTF-I
To determine if MDM2 could induce the ubiquitinylation
of TTF-I, both proteins were co-expressed in vivo with
epitope-tagged ubiquitin, and cells treated with the





Figure 2. TTF-I is ubiquitinylated and its abundance is regulated by
MDM2. (A) After re-addition of doxycycline to inactivate transgene
expression in induced (Dox-) B6 cells, FLAG-TTF-I levels decay
from the steady state with a half-time of between 6 and 7h. Relative
TTF-I levels were estimated in comparison with 25, 50, 75 and 100%
loading of the steady-state expressing cells before re-addition of
doxycyclin. (B) TTF-I is poly-ubiquitinylated and this ubiquitinylation
is inhibited by ARF. FLAG-TTF-I was expressed along with
HA-tagged Ubiquitin (Ub) and HA-mARF in HEK293T cells,
complexes were immunoprecipitated (IP) with anti-FLAG antibody
and immunoblotted (IB) using anti-HA and anti-FLAG antibodies.
Lysate refers to the whole-cell lysates before IP. Arrowheads in the
upper panel indicate discrete mono-, di-, tri- and tetra-ubiquitinylations
(1–4 Ubiq) of TTF-I. (C) Expression of increasing levels of Myc-tagged
MDM2 limits the accumulation of FLAG-TTF-I. Whole-cell lysates
from transiently transfected HEK293T cells were immunoblotted
Figure 2. Continued
using anti-FLAG, anti-Myc and anti-ﬁbrillarin (Fib) antibodies.
(D) Transient expression of Myc-MDM2 in NIH3T3 cells strongly de-
creases nucleolar level of endogenous TTF-I. Non-transfected and
Myc-MDM2 transfected cells were ﬁxed and processed for immuno-
ﬂuorescence with anti-TTF#3, anti-MDM2 (2A10) as described in
‘Materials and Methods’ section (see also Supplementary Figure S3).
Nucleic Acids Research, 2012,Vol.40, No. 12 5361ubiquitinylated TTF-I. Wild-type MDM2 expression
induced a signiﬁcant enhancement of TTF-I ubiquitiny-
lation at the expense of unmodiﬁed TTF-I (Figure 3A).
To test if the E3 ligase activity of MDM2 was required,
the ability of wild-type MDM2 and the inactive C462A
MDM2 mutant to induce ubiquitinylation of TTF-I was
compared (Figure 3B). Co-expression of MDM2 again
enhanced TTF-I ubiquitinylation, while co-expression of
mutant MDM2 reduced ubiquitinylation to near back-
ground level. Thus, ubiquitinylation of TTF-I is depend-
ent on the presence of catalytically active MDM2.
MDM2 interacts directly with TTF-I
The ability of MDM2 to induce ubiquitinylation of TTF-I
suggested that TTF-I was also a direct substrate of this
E3-ligase. Since MDM2 usually interacts speciﬁcally with
its substrates, as do other E3-ligases (36), we asked if it
also interacts with TTF-I. In vitro expressed Myc-MDM2
was pulled down by the DNA-binding domain of TTF-I,
showing that the two proteins are able to interact directly
and speciﬁcally with each other (Figure 4A). When
co-expressed in HEK293T cells, wild-type FLAG-TTF-I
and MDM2 speciﬁcally co-immunoprecipitated and hence
also interacted in vivo (Figure 4B). Expression of
sub-fragments of TTF-I showed independent interactions
of MDM2 with both the N-terminal regulatory domain
(a.a. 2–210) and the C-terminal DNA-binding domain
(a.a. 471–859), but not with the central domain (see
again Figure 4B). Endogenous TTF-I was also found to
co-immunoprecipitate with endogenous MDM2 from
NIH3T3 cells treated with the proteasome inhibitor
MG132 (Figure 4C). Three independent monoclonal
antibodies displayed signiﬁcantly different efﬁciencies of
immunoprecipitation of MDM2, and these efﬁciencies
correlated with the levels of TTF-I co-immuno-
precipitation, underlining the speciﬁcity of the endogenous
interaction. Further, the endogenous TTF-I fraction
immunoprecipitated with endogenous MDM2 under the
conditions of proteasome inhibition displayed a very
distinct smearing towards higher molecular weights. This
was not detected in the bulk endogenous (input) TTF-I
and was consistent with extensive ubiquitinylation. Finer
mapping of the interaction within the regulatory
N-terminal domain, this time using YFP as epitope tag,
conﬁrmed the N- and C-terminal interactions and showed
that a.a. 2–210 and 121–470 interact with MDM2, but
that a.a. 121–210 was insufﬁcient (Figure 4B and D).
These data suggested that the key N-terminal interaction
sites lay between a.a. 121 and 210, but that immediately
ﬂanking sequences also played a role in stabilizing the
interaction (summarized in Figure 4E).
ARF competes with the MDM2 interaction and inhibits
TTF-I ubiquitinylation
Surprisingly, the N-terminal MDM2 interaction domain
of TTF-I overlapped its previously mapped ARF inter-
action domain (Figure 4E). This potentially explained
why ARF was able to inhibit TTF-I ubiquitinylation
(Figure 2B). In fact, ARF effectively competed the inter-
action of MDM2 with TTF-I and formed its own complex
with TTF-I (Figure 5A). MDM2 or ARF expression with
TTF-I produced the expected MDM2-TTF and
ARF–TTF complexes. But when both ARF and MDM2
were co-expressed with TTF-I, the ARF–TTF complex
was formed at the expense of the MDM2–TTF complex.
This displacement of MDM2 by ARF also corresponded
with the inhibition of TTF-I ubiquitinylation (Figure 5B).
In the absence of proteasome inhibition, TTF-I was
ubiquitinylated and interacted with MDM2 as expected.
However, when ARF was introduced both
ubiquitinylation of TTF-I and its interaction with
MDM2 were inhibited. This again supports the notion
that TTF-I is a direct target of MDM2 ubiquitinylation.
DISCUSSION
In a previous study, we showed that the tumour suppres-
sor ARF (p19
ARF/p14
ARF) interacts directly with the
rRNA gene factor TTF-I in both mouse and human
(13). The study demonstrated that TTF-I is an essential
factor for transcription of the rRNA genes and for
A
B
Figure 3. MDM2 induces ubiquitinylation of TTF-I dependent on its
E3 ubiquitin ligase activity. (A) Increasing levels of MDM2 induce
TTF-I poly-ubiquitinylation. FLAG-TTF-I, HA-Ubiquitin (HA-Ub)
and increasing levels of Myc-MDM2 were co-expressed in HEK293T
cells, in the presence of the proteasome inhibitor MG132, and FLAG
immunoprecipitates (IP) probed with anti-FLAG and anti-HA
antibodies in comparison with the whole-cell lysates. (B) TTF-I
ubiquitinylation is abrogated by the C462A point mutation of
MDM2 that inactivates the ubiquitin ligase activity (MDM2(C462A))
(22,23). FLAG-TTF-I, HA-Ubiquitin and wild type (WT) or inactive
MDM2 (C462A) were co-expressed as in (A) in the presence of
MG132, and FLAG immunoprecipitates probed with anti-FLAG and
anti-HA antibodies.
5362 Nucleic Acids Research, 2012,Vol.40, No. 12processing of their primary transcripts 47/45S pre-rRNA.
ARF inhibits both rRNA gene transcription and process-
ing by inducing the displacement of TTF-I from the
nucleolus. In the absence of ARF, TTF-I shuttles
between nucleolus and nucleoplasm with the aid of the
chaperone NPM/B23. In the present study, we ﬁnd that
the abundance of TTF-I is critical for ribosome biogen-
esis. Conditional over-expression of TTF-I phenocopied
its depletion and caused both the inhibition of 45S





Figure 4. MDM2 directly interacts with TTF-I. (A) Recombinant His-tagged TTF-I (a.a. 471–859) was expressed in E. coli BL21, immobilized on
Ni
2+ NTA-Agarose and used in pull-down assays with myc-tagged MDM2 expressed in vitro by coupled transcription/translation. Leftmost tracks
show the input myc-MDM2 and the rightmost and central tracks respectively show the recovery of MDM2 on immobilized TTF-I (TTF) and on
Ni
2+-agarose pre-incubated with an extract from non-expressing BL21 E. coli (Ctrl). (B) MDM2 interacts in vivo with both N- and C-terminal
domains of TTF-I. Full-length and truncated FLAG-TTF-I proteins (a.a. 2–210, 211–470 and 471–859) were co-expressed with Myc-MDM2 in
HEK293T cells, and FLAG immunoprecipitates (IP) probed with anti-FLAG and anti-Myc antibodies. (C) Endogenous TTF-I also interacts with
endogenous MDM2 in NIH3T3 cells. Cells were treated with 20mM MG132 for 12h and whole-cell protein extracts immunoprecipitated with each
of three MDM2-speciﬁc antibodies (3G5, 4B11 and 2A10) or a control non-speciﬁc antibody (IgG), and immunoprecipitates were probed for MDM2
and TTF (anti-TTF#3). The higher-molecular-weight ‘‘smear’’ seen for immunoprecipitated endogenous TTF-I is consistent with its ubiquitinylation.
(D) To map the MDM2 interaction sites on TTF-I, YFP fusion proteins were co-expressed with Myc-MDM2 in HEK293T cells, and YFP
immunoprecipitates probed with anti-Myc and anti-YFP antibodies. (E) Summary of the functional sub-domains of TTF and the interactions
with MDM2 and ARF. The N-terminal activation/repression and autoregulatory domain and the sequence-speciﬁc DNA-binding domain are
indicated as are the Reb1 and Myb homologies.
Nucleic Acids Research, 2012,Vol.40, No. 12 5363abundance of TTF-I is a critical factor in determining the
rate of ribosome biogenesis. We ﬁnd that this abundance
is regulated by MDM2, and assays strongly support the
notion that this involves a direct interaction with, and
ubiquitinylation of, TTF-I (Figure 6A). Firstly, increased
levels of MDM2 enhance TTF-I ubiquitinylation and
reduce its cellular abundance as well as its concentration
in the nucleolus. Secondly, MDM2 interacts with TTF-I
both in vitro and in vivo. Hence, our data strongly suggest
that MDM2 regulates ribosome biogenesis by determining
the abundance of TTF-I. This is certainly not the only
mechanism that implicates MDM2 in ribosome biogen-
esis. For example, the state of ribosome biogenesis has
been shown to regulate the activity of MDM2 via inter-
actions with free ribosomal proteins (see ref. 37 for a
review). However, to our knowledge it is the ﬁrst demon-
stration that MDM2 may itself determine the rate of
ribosome biogenesis.
ARF is known to inhibit MDM2 via a direct inter-
action and, at least in part, by sequestering MDM2 in
A
B
Figure 5. MDM2 and ARF competitively regulate the ubiquitinylation of TTF-I. (A) ARF displaces MDM2 from TTF-I. FLAG-TTF-I, HA-ARF
and Myc-MDM2 were co-expressed in HEK293T cells, and FLAG immunoprecipitates (IP) were probed with anti-FLAG, anti-HA and anti-Myc
antibodies. (B) ARF displaces MDM2 from TTF-I and inhibits its ubiquitinylation. FLAG-TTF-I, HA-Ubiquitin, HA-ARF and Myc-MDM2 were
co-expressed in HEK293T cells, and FLAG immunoprecipitates probed with anti-FLAG, anti-HA and anti-Myc antibodies. Ubiquitinylation of
TTF-I is indicated in the upper panel (TTF-Ub).
5364 Nucleic Acids Research, 2012,Vol.40, No. 12the nucleolus (38). This latter mode of inhibition has been
the subject of some controversy (39–41); however, it may
be explained by the reduced accessibility of MDM2 to
antibody detection once it is displaced to the nucleolus
(see Supplementary Figure S5 and Figure 5B of ref. 13).
As we now show, ARF is also able to compete with
MDM2 for binding to TTF-I. Hence, ARF most likely
suppresses the ubiquitinylation of TTF-I both by
displacing MDM2 from it and by inhibiting MDM2
function. The ability of ARF to prevent re-entry of
TTF-I into the nucleolus (13) could provide yet another
mechanism to inhibit its interaction with MDM2
(Figure 6B). Thus, it might be expected that ARF would
enhance the cellular abundance of TTF-I by preventing its
ubiquitinylation and consequent degradation. Despite
this, bulk TTF-I levels remain constant during ARF
induction (Supplementary Figure S4A). We do detect a
mild degree of stabilization of existing TTF-I protein in
the presence of ARF (Supplementary Figure S4B).
However, this stabilization is balanced by the suppression
of new protein synthesis exerted by ARF (Supplementary
Figure S4C). Hence, TTF-I levels in cells expressing ARF
are probably maintained constant by the opposing effects
of enhanced TTF-I stability and reduced synthesis.
Suppression of TTF-I ubiquitinylation may then be
an unavoidable by-product of ARF’s functions in inhibit-
ing MDM2 and hence stabilizing p53 (42–45), and of
inhibiting ribosome biogenesis by displacing TTF-I from
the nucleolus (13). However, the ability to maintain a
constant TTF-I level by preventing its degradation
during ARF induction could also play an important bio-
logical role, since it would allow a rapid re-establishment
of normal ribosome biogenesis when ARF expression is
no longer required, such as for example after the success-
ful repair of cell damage.
Previous data have suggested that TTF-I regulates
rRNA gene activation/silencing and mediates RPI tran-
scription termination (46–48). In our study conditional
over-expression of TTF-I had no signiﬁcant effect on
these functions. The number of active rRNA genes
remained constant over many days (Supplementary
Figure S1A and S1B), despite a very signiﬁcant reduction
in rRNA synthesis (Figure 1B and C). TTF is known to
bind to the promoter proximal and 45S rRNA termination
sites and we have conﬁrmed these observations both
in vitro (Lessard,F., unpublished data) and in vivo (13).
However, we also did not detect any signiﬁcant
change in the distribution and level of 45S rRNA 30
termini after conditional over-expression of TTF-I
(Supplementary Figure S1C). Thus, despite TTF-I being
an essential factor for rRNA gene transcription and its
abundance being a critical regulator of both 45S
pre-rRNA transcription and processing, its mechanism
of action is still unclear and will require further study.
AB
Figure 6. MDM2 in the control of TTF-I. (A) TTF-I normally shuttles between nucleoplasm and nucleolus. [This occurs with the aid of the
chaperone NPM/B23 and a nucleolar localization sequence within the N-terminal regulatory domain of TTF-I (13).] While cycling through the
nucleoplasm, TTF-I may interact with MDM2 which then ubiquitinylates it and targets it for degradation. (B) Induction of ARF by oncogenic stress
or by differentiation will inhibit MDM2 function, in part by sequestering it in the nucleolus. ARF also prevents TTF-I from re-entering the nucleolus
and MDM2-dependent ubiquitinylation by competitive binding to a common site on TTF-I. The darker blue region represents the nucleoplasm and
the lighter blue region the nucleolus.
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